Clinical Trial Update: Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the immunogenicity and safety of subcutaneously administered Avonex (Interferon beta-1a) in multiple sclerosis patients was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2014-05-07